There are 2789 resources available
1004P - Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability
Presenter: Michael J. Overman
Session: ePoster Display
1005P - A new platform of personalized neoantigen cancer vaccines directed by checkpoint inhibitor antibodies to improve cancer immunity
Presenter: Yuji Mishima
Session: ePoster Display
1006P - ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors
Presenter: Sarina Piha-Paul
Session: ePoster Display
1007P - T-cells transgenic for a highly potent PRAME-specific TCR and a chimeric PD1-41BB co-stimulatory receptor represent a promising approach for the treatment of solid tumors
Presenter: Maja Bürdek
Session: ePoster Display
1008P - cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility
Presenter: Mithun Khattar
Session: ePoster Display
1009P - Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey
Presenter: Patrizia Comoli
Session: ePoster Display
1010P - Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008
Presenter: Thomas Eigentler
Session: ePoster Display
1011P - FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results
Presenter: Aung Naing
Session: ePoster Display
1012P - Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade
Presenter: WON SUK LEE
Session: ePoster Display
1013P - Similar overall survival in tebentafusp-treated 2L+ metastatic uveal melanoma regardless of prior immunotherapy
Presenter: Josep M. Piulats
Session: ePoster Display